Breast Cancer Genomics

Bioactive Cardinane Sesquiterpenes from the Stems of Alangium salviifolium

“…It hasb een estimated that 1.5 million new cases are diagnosed every year. [12] Approximately 60 %o fp remenopausal women and7 5% of postmenopausal women with breast cancer are exposed to higher estrogen levels in cancer cells. The enzyme aromatase (CYP19)i sr esponsible for the production of estrogens by aromatization of the Ar ing in the steroid androgens.…”

“…The cytotoxic, cancer chemopreventive, and aroma-tase inhibition activities of some compounds werea lso reported. [4] Continuing this investigation of the dichloromethane extract, the isolation and structure elucidation of seven new alangenes A-G (1-7)a nd five known compounds (8)(9)(10)(11)(12)o ft he cardinane sesquiterpenes framework are now reported, together with an evaluation of their cytotoxic and aromatase inhibition properties.…”

“…

Ad ichloromethane extract of the stems of Alangium salviifolium afforded twelve cardinane sesquiterpenes, seven of which are new alangenes A-G (1-7)a nd five known compounds (8)(9)(10)(11)(12). Their structures were elucidated on the basis of spectroscopict echniques including UV,I R, and NMR spectroscopies, and mass spectrometry.M ost of the tested compounds exhibited very potent aromatase inhibition properties, especially in the case of the cardinane sesquiterpenes 1, 5-8,a nd 10 (IC 50 values of 0.09, 0.13, 0.30, 0.06, 2.05, and 1.19 mm,r espectively), which are significantly better than that of the positive control (ketoconazole, IC 50 of 2.4 mm).

…”

The anticancer properties of phytochemical extracts from Salvia plants

“…57 Furthermore, characterizing the expression of three receptors, namely, the estrogen receptor (ER), progesterone receptor, and the human epidermal growth factor receptor 2 (HER2), has been an important part of the standard assessment of breast tumors in current clinical practice. 7 Since hormone replacement therapy was considered to increase the risk of breast cancer, 58,59 investigation of other possible alternatives has gained importance.…”

Translating genetics beyond bench and bedside: A comparative perspective on health care infrastructures for ‘familial’ breast cancer

“…While germline and somatic approaches to cancer genomics are different, they share certain characteristics of interest from the viewpoint of translation. Both (should) allow more sophisticated classification of disease (risk) into distinct subcategories and earlier intervention more tailored to affected sub-populations (Bydoun et al, 2014). At the same time, a focus on familial cancer risks allows us to see how uses of genomics are established as routines, how the limits of molecular technologies are confronted (since only around 30% of familial breast cancers has a known genetic background (Shiovitz and Korde, 2015, Foulkes, 2008)), and how technicalities of risk stratification intersect with the social dimensions of health care infrastructures to bring genomics to the population.…”